PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Endocyte Announces Closing of Public Offering of Common Stock
WEST LAFAYETTE, Ind. , Sept. 14, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the closing of an underwritten registered public offering of an aggregate of
View HTML
Toggle Summary Endocyte Announces Pricing of Public Offering of Common Stock
WEST LAFAYETTE, Ind. , Sept. 11, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today the pricing of an underwritten registered public offering of 9,459,460 shares of its
View HTML
Toggle Summary Endocyte Announces $175.0 Million Proposed Public Offering of Common Stock
WEST LAFAYETTE, Ind. , Sept. 10, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq Global Market:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, announced today that it intends to offer and sell $175.0 million of its common stock in an
View HTML
Toggle Summary Endocyte Announces FDA Acceptance of Radiographic Progression Free Survival (rPFS) as an Alternative Primary Endpoint of the VISION Trial in Addition to Overall Survival (OS)
Demonstrating benefit in rPFS versus control, with no detriment to OS, sufficient for full approval A positive assessment on either rPFS or OS is sufficient for full approval rPFS analysis expected late 2019, approximately one year ahead of final OS analysis  Conference Call Today at 8:30 a.m.
View HTML
Toggle Summary Endocyte to Present at Wells Fargo Securities 2018 Healthcare Conference
WEST LAFAYETTE, Ind. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at the Wells Fargo Securities 2018 Healthcare
View HTML
Toggle Summary Endocyte Announces Presentations at the CAR-TCR Summit 2018
WEST LAFAYETTE, Ind. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that data from the Company’s chimeric antigen receptor T-cell (CAR T) adaptor molecule (CAM)
View HTML
Toggle Summary Endocyte Announces Presentations at the American Chemical Society (ACS) National Meeting & Exposition
WEST LAFAYETTE, Ind. , Aug. 17, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that two posters will be presented by Endocyte scientists at the ACS National Meeting & Exposition
View HTML
Toggle Summary Endocyte to Present at the 2018 Wedbush PacGrow Healthcare Conference
WEST LAFAYETTE, Ind. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company’s management team will present at the 2018 Wedbush PacGrow Healthcare Conference on
View HTML
Toggle Summary Endocyte Provides Second Quarter 2018 Financial Results and Operational Update
                       -Initiated phase 3 VISION study of 177 Lu-PSMA-617 in mCRPC-                  -Secured commercial supply of no-carrier-added Lutetium-177 through 2035 - -Investigational new drug (IND) filing for EC17/CAR T-cell therapy on track for fourth quarter 2018 -           
View HTML
Toggle Summary Endocyte Announces Second Quarter 2018 Financial Results and Operational Update Call
WEST LAFAYETTE, Ind. , July 25, 2018 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that the company will host a conference call on Tuesday, July 31st , at 8:30 a.m.
View HTML